RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:329931

C3 glomerulonephritis

low confidenceSubtype of disorder

Publications

1,797

Trials

10

Interventional, condition-specific

Researchers

1,354

Distinct authors in sample

Gene link

C3, CFB, CFH

Definitive

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A histological subtype of C3 glomerulopathy characterized by C3 deposition in renal tissue in the absence or near-absence of immunoglobulin deposits, in a patient with the classic clinical features of glomerulonephritis and the electron microscopic findings of predominant subendothelial, occasionally subepithelial (so-called ''humps''), and intramembranous deposits, but without the typical electron-dense deposits of dense deposit disease.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

complement-mediated membranoproliferative glomerulonephritis · nephropathy due to CFHR5 deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — C3, CFB, CFH, CFHR5, CFI

  2. LiteraturePresent

    1,797 matched papers (1,289 in last 10 years) Source

  3. Phenotype characterisedPresent

    9 HPO annotations (e.g. Glomerulonephritis; Stage 5 chronic kidney disease; Mesangial matrix expansion) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    10 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (C3, CFB, CFH…).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

9

Associated phenotypes · MONDO:0013892

  • Glomerulonephritis
  • Stage 5 chronic kidney disease
  • Mesangial matrix expansion
  • Thickening of glomerular capillary wall
  • Glomerular subendothelial electron-dense deposits

Showing 5 of 9 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

2

Drugs / clinical candidates · MONDO_0013892

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,797

1,797 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,797 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,289 in the last 10 years · low confidence

Phrase hits: 1,230 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,354

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Caravaca-Fontán F7 papers · 2026

    Department of Nephrology, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.

    Papers in Europe PMC
  2. 02
    Praga M6 papers · 2026

    Department of Medicine, Complutense University, Madrid, Spain.

    Papers in Europe PMC
  3. 03
    Sethi S6 papers · 2026

    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

    Papers in Europe PMC
  4. 04
    Fervenza FC4 papers · 2026

    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.

    Papers in Europe PMC
  5. 05
    Emma F3 papers · 2025

    Division of Nephrology, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy.

    Papers in Europe PMC
  6. 06
    Lee H3 papers · 2025

    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

    Papers in Europe PMC
  7. 07
    Nagano C3 papers · 2025

    Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.

    Papers in Europe PMC
  8. 08
    Nozu K3 papers · 2025

    Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.

    Papers in Europe PMC
  9. 09
    Ohashi K3 papers · 2026

    Department of Human Pathology, Tokyo Medical and Dental University, Tokyo.

    Papers in Europe PMC
  10. 10
    Sawai T3 papers · 2025

    Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

10

interventional trials for this specific condition

10 interventional trials matched this specific condition name; 1 currently recruiting in our sample.

Data as of 11 September 2026 · last trial check 28 July 2026

10 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.5th percentile).

low confidence · 92.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

10 interventional trials matched after quoted-phrase search and title/condition post-filter.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (3)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for C3 glomerulonephritis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("C3 glomerulonephritis" OR "complement-mediated membranoproliferative glomerulonephritis" OR "nephropathy due to CFHR5 deficiency") OR ("C3 syndrome" OR "C3-related" OR "CFB syndrome" OR "CFB-related" OR "CFH syndrome" OR "CFH-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"C3 glomerulonephritis" OR "complement-mediated membranoproliferative glomerulonephritis" OR "nephropathy due to CFHR5 deficiency"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 10 interventional · 0 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1797) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T13:57:24.339Z